Abstract:Gene therapy is a flourishing field with the potential to revolutionize the treatment of genetic diseases. The emergence of CRISPR-Cas9 has significantly advanced targeted and efficient genome editing. Although CRISPR-Cas9 has demonstrated promising potential applications in various genetic disorders, it faces limitations in simultaneously targeting multiple genes. Novel CRISPR systems, such as Cas12 and Cas13, have been developed to overcome these challenges, enabling multiplexing and providing unique advantages. Cas13, in particular, targets mRNA instead of genomic DNA, permitting precise gene expression control and mitigating off-target effects. This review investigates the potential of Cas12 and Cas13 in ocular gene therapy applications, such as suppression of inflammation and cell death. In addition, the capabilities of Cas12 and Cas13 are explored in addressing potential targets related with disease mechanisms such as aberrant isoforms, mitochondrial genes, cis-regulatory sequences, modifier genes, and long non-coding RNAs. Anatomical accessibility and relative immune privilege of the eye provide an ideal organ system for evaluating these novel techniques' efficacy and safety. By targeting multiple genes concurrently, CRISPR-Cas12 and Cas13 systems hold promise for treating a range of ocular disorders, including glaucoma, retinal dystrophies, and age-related macular degeneration. Nonetheless, additional refinement is required to ascertain the safety and efficacy of these approaches in ocular disease treatments. Thus, the development of Cas12 and Cas13 systems marks a significant advancement in gene therapy, offering the potential to devise effective treatments for ocular disorders.

Applications Of Crispr/Cas9 In Retinal Degenerative Diseases

Exploring retinal degenerative diseases through CRISPR-based screening

Therapeutic Applications of CRISPR/Cas9 Gene Editing Technology for the Treatment of Ocular Diseases

Delivery strategies for CRISPR/Cas genome editing tool for retinal dystrophies: challenges and opportunities

CRISPR Interference–Potential Application in Retinal Disease

Toward the Treatment of Inherited Diseases of the Retina Using CRISPR-Based Gene Editing

Unleashing the potential of CRISPR multiplexing: Harnessing Cas12 and Cas13 for precise gene modulation in eye diseases

Novel Therapeutic Approaches for the Treatment of Retinal Degenerative Diseases: Focus on CRISPR/Cas-Based Gene Editing

Comparison of CRISPR/Cas endonucleases for in vivo retinal gene editing

Gene Editing Preserves Visual Functions in a Mouse Model of Retinal Degeneration

The Potential of Gene Editing Technologies in the Treatment of Hereditary Retinal Diseases

CRISPR/Cas9 Mechanism and Applications Progression

CRISPR/SaCas9-based gene editing rescues photoreceptor degeneration throughout a rhodopsin-associated autosomal dominant retinitis pigmentosa mouse model

Development and application of CRISPR/Cas9 technologies in genomic editing.

Precision genome editing in the eye

cRGD-modified hybrid lipopolymeric nanoplexes for gene editing in the posterior segment of the eye

Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy

Applications and Research Advances in the Delivery of CRISPR/Cas9 Systems for the Treatment of Inherited Diseases

In Vivo CRISPR/Cas9 Gene Editing Corrects Retinal Dystrophy in the S334ter-3 Rat Model of Autosomal Dominant Retinitis Pigmentosa

The power and the promise of CRISPR/Cas9 genome editing for clinical application with gene therapy

CRISPR/Cas9 therapeutics: progress and prospects